224 related articles for article (PubMed ID: 37192158)
1. IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing.
Pan Y; Phillips JW; Zhang BD; Noguchi M; Kutschera E; McLaughlin J; Nesterenko PA; Mao Z; Bangayan NJ; Wang R; Tran W; Yang HT; Wang Y; Xu Y; Obusan MB; Cheng D; Lee AH; Kadash-Edmondson KE; Champhekar A; Puig-Saus C; Ribas A; Prins RM; Seet CS; Crooks GM; Witte ON; Xing Y
Proc Natl Acad Sci U S A; 2023 May; 120(21):e2221116120. PubMed ID: 37192158
[TBL] [Abstract][Full Text] [Related]
2. Natural high-avidity T-cell receptor efficiently mediates regression of cancer/testis antigen 83 positive common solid cancers.
Li Q; Hu W; Liao B; Song C; Li L
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35798537
[TBL] [Abstract][Full Text] [Related]
3. Discovery of U2AF1 neoantigens in myeloid neoplasms.
Biernacki MA; Lok J; Black RG; Foster KA; Cummings C; Woodward KB; Monahan T; Oehler VG; Stirewalt DL; Wu D; Rongvaux A; Deeg HJ; Bleakley M
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38164756
[TBL] [Abstract][Full Text] [Related]
4. Physical and in silico immunopeptidomic profiling of a cancer antigen prostatic acid phosphatase reveals targets enabling TCR isolation.
Mao Z; Nesterenko PA; McLaughlin J; Deng W; Burton Sojo G; Cheng D; Noguchi M; Chour W; DeLucia DC; Finton KA; Qin Y; Obusan MB; Tran W; Wang L; Bangayan NJ; Ta L; Chen CC; Seet CS; Crooks GM; Phillips JW; Heath JR; Strong RK; Lee JK; Wohlschlegel JA; Witte ON
Proc Natl Acad Sci U S A; 2022 Aug; 119(31):e2203410119. PubMed ID: 35878026
[TBL] [Abstract][Full Text] [Related]
5. Development of a T cell receptor targeting an HLA-A*0201 restricted epitope from the cancer-testis antigen SSX2 for adoptive immunotherapy of cancer.
Abate-Daga D; Speiser DE; Chinnasamy N; Zheng Z; Xu H; Feldman SA; Rosenberg SA; Morgan RA
PLoS One; 2014; 9(3):e93321. PubMed ID: 24681846
[TBL] [Abstract][Full Text] [Related]
6. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
[TBL] [Abstract][Full Text] [Related]
7. Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response.
He J; Xiong X; Yang H; Li D; Liu X; Li S; Liao S; Chen S; Wen X; Yu K; Fu L; Dong X; Zhu K; Xia X; Kang T; Bian C; Li X; Liu H; Ding P; Zhang X; Liu Z; Li W; Zuo Z; Zhou P
Cell Res; 2022 Jun; 32(6):530-542. PubMed ID: 35165422
[TBL] [Abstract][Full Text] [Related]
8. Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes.
Simon P; Omokoko TA; Breitkreuz A; Hebich L; Kreiter S; Attig S; Konur A; Britten CM; Paret C; Dhaene K; Türeci Ö; Sahin U
Cancer Immunol Res; 2014 Dec; 2(12):1230-44. PubMed ID: 25245536
[TBL] [Abstract][Full Text] [Related]
9. Identification of neoepitope reactive T-cell receptors guided by HLA-A*03:01 and HLA-A*11:01 immunopeptidomics.
Ade CM; Sporn MJ; Das S; Yu Z; Hanada KI; Qi YA; Maity T; Zhang X; Guha U; Andresson T; Yang JC
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37758652
[TBL] [Abstract][Full Text] [Related]
10. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.
de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M
Front Immunol; 2021; 12():592031. PubMed ID: 34335558
[TBL] [Abstract][Full Text] [Related]
11. Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma.
Murata K; Nakatsugawa M; Rahman MA; Nguyen LT; Millar DG; Mulder DT; Sugata K; Saijo H; Matsunaga Y; Kagoya Y; Guo T; Anczurowski M; Wang CH; Burt BD; Ly D; Saso K; Easson A; Goldstein DP; Reedijk M; Ghazarian D; Pugh TJ; Butler MO; Mak TW; Ohashi PS; Hirano N
Elife; 2020 Apr; 9():. PubMed ID: 32314731
[TBL] [Abstract][Full Text] [Related]
12. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract][Full Text] [Related]
13. Global analysis of HLA-A2 restricted MAGE-A3 tumor antigen epitopes and corresponding TCRs in non-small cell lung cancer.
Zhang B; Ren Z; Zhao J; Zhu Y; Huang B; Xiao C; Zhang Y; Deng J; Mao L; Tang L; Lan D; Gao L; Zhang H; Chen G; Luo OJ
Theranostics; 2023; 13(13):4449-4468. PubMed ID: 37649599
[No Abstract] [Full Text] [Related]
14. Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy.
Li G; Mahajan S; Ma S; Jeffery ED; Zhang X; Bhattacharjee A; Venkatasubramanian M; Weirauch MT; Miraldi ER; Grimes HL; Sheynkman GM; Tilburgs T; Salomonis N
Sci Transl Med; 2024 Jan; 16(730):eade2886. PubMed ID: 38232136
[TBL] [Abstract][Full Text] [Related]
15. A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.
Ma Q; Garber HR; Lu S; He H; Tallis E; Ding X; Sergeeva A; Wood MS; Dotti G; Salvado B; Ruisaard K; Clise-Dwyer K; John LS; Rezvani K; Alatrash G; Shpall EJ; Molldrem JJ
Cytotherapy; 2016 Aug; 18(8):985-994. PubMed ID: 27265873
[TBL] [Abstract][Full Text] [Related]
16. Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies.
Tubb VM; Schrikkema DS; Croft NP; Purcell AW; Linnemann C; Freriks MR; Chen F; Long HM; Lee SP; Bendle GM
J Immunother Cancer; 2018 Jul; 6(1):70. PubMed ID: 30001747
[TBL] [Abstract][Full Text] [Related]
17. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma.
Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289
[TBL] [Abstract][Full Text] [Related]
18. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P; Leung WK; Woods M; Choi JM; Rodriguez-Plata CM; Maknojia A; Mosquera A; Somes LK; Joubert J; Manliguez A; Ranjan R; Burt B; Lee HS; Zhang B; Fuqua S; Rooney C; Leen AM; Hoyos V
Cytotherapy; 2024 Mar; 26(3):266-275. PubMed ID: 38231165
[TBL] [Abstract][Full Text] [Related]
19. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E.
Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M
J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151
[TBL] [Abstract][Full Text] [Related]
20. Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies.
Schuster IG; Busch DH; Eppinger E; Kremmer E; Milosevic S; Hennard C; Kuttler C; Ellwart JW; Frankenberger B; Nössner E; Salat C; Bogner C; Borkhardt A; Kolb HJ; Krackhardt AM
Blood; 2007 Oct; 110(8):2931-9. PubMed ID: 17626842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
